肿瘤研究与临床
腫瘤研究與臨床
종류연구여림상
CANCER RESEARCH AND CLINIC
2015年
5期
328-331
,共4页
周丽娜%王李强%徐海源%计张奕%唐敏%陈敏斌
週麗娜%王李彊%徐海源%計張奕%唐敏%陳敏斌
주려나%왕리강%서해원%계장혁%당민%진민빈
胰腺肿瘤%替吉奥%吉西他滨
胰腺腫瘤%替吉奧%吉西他濱
이선종류%체길오%길서타빈
Pancreatic neoplasms%S-1%Gemcitabine
目的 探讨替吉奥治疗晚期胰腺癌的临床疗效和安全性.方法 回顾性分析收治的行替吉奥单药或替吉奥联合吉西他滨一线治疗的晚期胰腺癌患者46例,其中替吉奥组(A组)24例,替吉奥联合吉西他滨组(B组)22例,分析两组患者的近期疗效、疾病进展时间、生存期及安全性.结果 A组的客观缓解率、疾病控制率、中位无进展生存期、中位总生存期、1年生存率分别为20.8％(5/24)、66.7 ％(16/24)、4.8个月、9.6个月、12.5％,B组分别为27.3 ％(6/22)、72.7％(16/22)、5.9个月、10.3个月、22.7％,A组的客观缓解率、疾病控制率、中位无进展生存期、中位总生存期、1年生存率均略低于B组,但差异均无统计学意义(均P＞0.05).全组患者不良反应较轻,无治疗相关的死亡事件发生,A组患者的不良反应大部分小于B组,其中A组的白细胞减少、中性粒细胞减少、血小板减少发生率低于B组(P＜0.05).结论 替吉奥单药或联合吉西他滨治疗晚期胰腺癌疗效无差别,但替吉奥单药组不良反应较小,可作为一线治疗.
目的 探討替吉奧治療晚期胰腺癌的臨床療效和安全性.方法 迴顧性分析收治的行替吉奧單藥或替吉奧聯閤吉西他濱一線治療的晚期胰腺癌患者46例,其中替吉奧組(A組)24例,替吉奧聯閤吉西他濱組(B組)22例,分析兩組患者的近期療效、疾病進展時間、生存期及安全性.結果 A組的客觀緩解率、疾病控製率、中位無進展生存期、中位總生存期、1年生存率分彆為20.8％(5/24)、66.7 ％(16/24)、4.8箇月、9.6箇月、12.5％,B組分彆為27.3 ％(6/22)、72.7％(16/22)、5.9箇月、10.3箇月、22.7％,A組的客觀緩解率、疾病控製率、中位無進展生存期、中位總生存期、1年生存率均略低于B組,但差異均無統計學意義(均P＞0.05).全組患者不良反應較輕,無治療相關的死亡事件髮生,A組患者的不良反應大部分小于B組,其中A組的白細胞減少、中性粒細胞減少、血小闆減少髮生率低于B組(P＜0.05).結論 替吉奧單藥或聯閤吉西他濱治療晚期胰腺癌療效無差彆,但替吉奧單藥組不良反應較小,可作為一線治療.
목적 탐토체길오치료만기이선암적림상료효화안전성.방법 회고성분석수치적행체길오단약혹체길오연합길서타빈일선치료적만기이선암환자46례,기중체길오조(A조)24례,체길오연합길서타빈조(B조)22례,분석량조환자적근기료효、질병진전시간、생존기급안전성.결과 A조적객관완해솔、질병공제솔、중위무진전생존기、중위총생존기、1년생존솔분별위20.8％(5/24)、66.7 ％(16/24)、4.8개월、9.6개월、12.5％,B조분별위27.3 ％(6/22)、72.7％(16/22)、5.9개월、10.3개월、22.7％,A조적객관완해솔、질병공제솔、중위무진전생존기、중위총생존기、1년생존솔균략저우B조,단차이균무통계학의의(균P＞0.05).전조환자불량반응교경,무치료상관적사망사건발생,A조환자적불량반응대부분소우B조,기중A조적백세포감소、중성립세포감소、혈소판감소발생솔저우B조(P＜0.05).결론 체길오단약혹연합길서타빈치료만기이선암료효무차별,단체길오단약조불량반응교소,가작위일선치료.
Objective To value the clinical efficacy and toxicity of S-1 compared to gemcitabine combined with S-1 in treatment of patients with advanced pancreatic cancer.Methods From January 2011 to December 2013,the data of 46 patients with advanced pancreatic cancer were analyzed retrospectively,including 24 patients receiving S-1 alone (group A) and 22 patients who received gemcitabine combined with S-1 (group B).The results were evaluated by objective response rate (ORR),disease control rate (DCR),survival time and safety.Results In group A the ORR was 20.8 ％ (5/24),DCR was 66.7 ％ (16/24),median progression-free survival was 4.8 months,median overall survival was 9.6 months,and 1 year survival was 12.5 ％.In group B the ORR was 27.3 ％ (6/22),DCR was 72.7 ％ (16/22),median progression-free survival was 5.9 months,median overall survival was 10.3 months,and 1 year survival was 22.7 ％.There was no significant difference between the two groups (P ＞ 0.05).The incidence rates of leukopenia,neutropenia and thrombopenia in group A were significantly lower than those in group B (P ＜ 0.05).Conclusion S-1 alone and gemcitabine combined with S-1 have similar effects in the treatment of advanced pancreatic cancer,but the toxicity of S-1 is mild and tolerable.
